Bonstein Sara

INSM CFO Bonstein Sara sold 8,272 shares at $116.18 ($961.0K) on 2026-05-13, retaining 71,486 shares post-trade.

Bonstein Sara, Chief Financial Officer of Insmed Inc, sold 8,272 shares at $116.18 for total proceeds of $961,040.96, retaining 71,486 shares post-transaction. The sale occurred against a backdrop of significant price weakness — INSM is currently -48.7% from its 52-week high of $212.75, with the stock down -25.6% over the prior 30 days and -26.6% over the prior 90 days. Her cross-ticker track record across 20 prior sells shows an average 90-day return of +40.0% after sales, reflecting a 90d well-timed rate of 30.00%, meaning her prior dispositions have generally been followed by stock appreciation rather than declines. At INSM specifically, 3 of her 5 prior sells were well-timed at the 90-day mark, with the January 2026 sells each followed by meaningful declines (-8.0%, -6.9%, and -5.5% at 90 days), while the July 2025 sells preceded substantial rallies of +60.9% and +61.9% at 90 days.

CFO Sara Bonstein sold 4,642 shares across 3 days (Jan 6-8) for $808,733.06 at blended avg $174.22

Sara Bonstein, Chief Financial Officer of INSMED Inc, executed three separate sales totaling 4,642 shares for $808,733.06 over January 6–8, reducing her holdings by 5.5% to 80,506 shares. The sales occurred at prices ($173.33–$175.07) notably above the current price of $170.27, and above the stock's recent 30-day decline of -12.3%, suggesting the CFO executed the sales into relative strength. INSMED is unprofitable (full-year net income was negative) despite 19.2% annual revenue growth, creating a valuation backdrop where senior officer disposition activity merits investor attention. Her prior five sales at this ticker showed zero well-timed outcomes at the 90-day horizon, indicating a pattern of selling that preceded subsequent gains rather than declines—a timing pattern inconsistent with data-driven risk reduction at the company level.

INSM CFO Sara Bonstein sells 58,400 shares for $5,996,093.50 on 2025-07-21; holds 73.5K post-trade

Sara Bonstein, Chief Financial Officer, executed 2 separate sales totaling 58,400 shares for $5,996,093.50 at an average price of $102.67 on 2025-07-21. This represents a -44.3% reduction from her pre-transaction holdings of 131.9K shares. The company remains unprofitable (net income of $-256.6M in the most recent full fiscal year) despite strong annual revenue growth of +19.2%, indicating structural losses continue to exceed top-line gains. Her prior transaction history at INSM shows 0 of measurable outcomes well-timed at the 90-day mark; her cross-ticker track record demonstrates a 71.43% well-timed rate on prior sells, but with recent same-ticker activity producing mixed 30-day results (ranging +1.3% to +11.0%), the data does not establish a clear pattern of accurate timing within this specific security. The substantial sale size and moderate holding reduction warrant monitoring of whether this signals a shift in CFO confidence or reflects portfolio management within normal parameters.

INSM CFO Bonstein sold 57.8K shares for $5.5M on 2025-07-07, reducing stake by 40.7%

CFO Sara Bonstein executed 2 separate sales totaling 57,764 shares for $5,537,460.17 at blended average price $95.86 on 2025-07-07, reducing her holdings from 141,781 shares to 84,017 shares (a -40.7% reduction). This large proportional reduction in CFO-level holdings is material given Bonstein's fiduciary position and the company's present operating profile: INSM posted negative net income of $-256,583,000.00 over its most recent full fiscal year while generating $92,823,000.00 in latest-quarter revenue. The stock has appreciated +36.5% over the prior 30 days and +48.8% over the prior 90 days, trading at $96.47 (close to the sale prices), placing it -8.9% from its 52-week high of $105.90. Bonstein's cross-ticker track record shows a 71.43% well-timed rate on 17 prior sells, but at this specific ticker her 5 most recent trades (3 on 2025-06-10, 2 on 2025-06-23, all sells) have no yet-measurable outcomes. The magnitude of this reduction and the CFO title warrant monitoring of near-term announcements and quarterly results to determine whether this reflects portfolio rebalancing or signals material shifts in insider perspective on valuation.

CFO Sara Bonstein sold 57,765 shares (38.2% of holdings) for $5.9M at blended avg $101.78 on 2025-06-23

Sara Bonstein, CFO of INSM, executed 2 separate sales on 2025-06-23 totaling 57,765 shares for $5,879,088.99, reducing her holdings from 151,301 to 93,536 shares (a 38.2% reduction). The sales occurred at $101.71 and $102.15, near the 52-week high of $105.90, while the stock has appreciated 55.3% over 30 days and 35.0% over 90 days. Across her cross-ticker open-market trade history, Bonstein's prior 15 sells averaged +15.4% 30-day and +3.5% 90-day returns, with a 71.43% well-timed rate, though her 5 prior trades specifically at INSM (all on 2025-06-10) have outcomes not yet measurable. INSM itself remains unprofitable with net income of -$256.6M on revenue of $92.8M, though annual revenue growth reached 19.2%, creating a context where a large executive equity reduction at elevated prices warrants investor attention.

CFO Bonstein sells 57.8K INSM shares for $5.1M in 6 transactions at $87.12–$91.66, reducing holdings 35.8%

Sara Bonstein, Chief Financial Officer of INSM, executed 6 separate sales on 2025-06-10 totaling 57,766 shares for $5,148,024.17 at prices ranging from $87.12 to $91.66 (blended average $89.12). This sale reduced her holdings by 35.8%, from 161,178 shares to 103,412 shares post-transaction. The current stock price of $96.88 is within 1.1% of the 52-week high of $97.98, and the stock has appreciated 47.4% over the past 30 days and 26.6% over 90 days. In same-ticker history, Bonstein's 3 prior measurable sales at INSM (Feb–May 2025) all produced negative 90-day returns, with a 100% well-timed rate at that measurement horizon, suggesting her sell decisions at this stock have preceded subsequent declines. Against this backdrop of near-peak pricing and a substantial reduction of her equity stake, the transaction merits monitoring given her track record on this ticker, though the filing does not indicate whether this sale was scheduled under a pre-established trading plan or discretionary.

CFO Sara Bonstein sells 10,504 shares at $67.47 avg; stock down 19.8% from 52-week high; strong same-ticker sell timing pattern continues.

Sara Bonstein, CFO of INSM, executed two separate sales totaling 10,504 shares for $708,681.44 on May 13–14, 2025, reducing her holdings by 8.8% to 108,359 shares. The blended average sale price of $67.47 sits just 0.21% above the current price of $67.22, but well below the 52-week high of $83.83 (stock is -19.8% from peak). Notably, Bonstein's prior five trades at INSM show a 100% well-timed rate at the 90-day mark—all three measurable prior sales preceded declines of -4.3% to -17.9% over the following quarter. Her cross-ticker track record also demonstrates a 60.00% well-timed sell rate with an average 90-day return of +11.2%, suggesting a consistent ability to exit before downside. The company remains unprofitable (net income of $-256.6M in the latest fiscal year) despite 19.2% annual revenue growth, creating fundamental headwinds that may inform her recent execution pattern.

CFO Sara Bonstein sold 18,322 shares (18.3K) at $80.31 avg; cross-ticker track record shows 0.00% well-timed rate on sells

Sara Bonstein, CFO of INSM, executed 2 separate sales totaling 18,322 shares for $1,471,394.16 on 2025-02-18, reducing her holdings by 13.4% from 137.2K to 118.9K shares. The blended average transaction price of $80.31 sits just 3.9% below the current price of $83.61 and only 0.3% below the 52-week high of $83.83, reflecting a near-peak exit. Her cross-ticker track record across 5 prior open-market sells shows a 0.00% well-timed rate at the 90-day mark (avg 90d return +52.3%), indicating a pattern of selling into strength rather than ahead of declines. At INSM specifically, her most recent measurable sales (2024-05-28 and 2024-05-29) saw the stock rise 50.4% and 54.2% respectively in the subsequent 90 days, showing poorly timed prior exits at this ticker. The company carries negative profitability ($-220.5M net income) despite 19.2% annual revenue growth, and the stock has rallied 8.9% over 30 days and 14.3% over 90 days—a backdrop in which insider selling near 52-week highs may warrant investor attention relative to the CFO's historical execution pattern.

CFO Sara Bonstein sold 18,321 shares at $80.00 across 2 days for $1,465,680, reducing holdings 11.8%.

Sara Bonstein, INSM's CFO, executed 2 separate sales totaling 18,321 shares for $1,465,680.00 (blended average $80.00), reducing her holdings from 155,506 to 137,185 shares (-11.8%). The sales occurred on 2025-02-11 and 2025-02-12, near the stock's 52-week high of $81.44, with the current price at $78.67 representing -3.4% from that peak. Reviewing her timing pattern at INSM specifically: her 2 prior measurable sales (2024-05-28 and 2024-05-29) each saw subsequent 90-day gains of +50.4% and +54.2% respectively, indicating these earlier sales were poorly timed as the stock rose after exit. Her cross-ticker track record shows a 0.00% well-timed rate across 3 prior open-market sells, with average 90-day returns of +52.3%, again reflecting a pattern where she sold before significant rallies. The company remains unprofitable with negative net income of $-220,524,000 in its most recent full fiscal year, though quarterly revenue of $93,425,000 reflects +24.4% annual growth.

CFO Sara Bonstein sold 28,390 shares (28.4K) of INSM at $80.90 for $2,296,751.00 on 2025-02-06

Sara Bonstein, CFO of INSMED Inc, executed a sale of 28,390 shares at $80.90, reducing her holdings by 15.4% to 155,506 shares. The stock closed at $79.95, near its 52-week high of $81.44, and the sale occurred after a strong 30-day rally of +21.6%. Her cross-ticker track record shows 2 prior open-market sells with an average 90-day return of +52.3%, indicating her prior sales were poorly timed relative to subsequent price appreciation; at INSM specifically, her 2 prior sells in May 2024 were similarly followed by substantial 90-day gains (+54.2% and +50.4%), suggesting a pattern where she has sold before further rallies. The company remains unprofitable with a net loss of $-220,524,000.00 in the latest full year, though revenue grew +24.4% year-over-year to $93,425,000.00 in the latest quarter.